Heterocyclic Estrogen Receptor Modulators for Metastatic Breast Cancer
Solution Overview
Problem
There is a need for new estrogen receptor-alpha (ER-a) targeting agents that are effective in treating metastatic disease and overcoming acquired resistance, particularly in hormone receptor-positive metastatic breast cancer post-anti-estrogen therapy, as existing therapies often fail to provide lasting tumor regression and are prone to resistance.
Innovation Solution
Development of compounds that act as estrogen receptor degraders or modulators, specifically designed to diminish estrogen receptor activity, including estrogen receptor antagonist and degrader compounds that can be administered as pharmaceutical compositions to treat various ER-related diseases and conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-estrogen therapies are used to treat hormone receptor-positive metastatic breast cancer, then initial tumor regression may be achieved, but treatment resistance develops and tumor regression is not lasting
Solution Approach 1:
The patent changes the mechanism of action parameter from simple receptor antagonism to receptor degradation. The compounds induce ubiquitination and proteasomal degradation of estrogen receptors, fundamentally altering how the therapy interacts with the target to achieve more durable tumor regression and overcome resistance
2Reliability
If existing estrogen receptor antagonists are used, then estrogen receptor activity is blocked, but acquired resistance develops reducing therapeutic effectiveness
Solution Approach 1:
The patent extracts the estrogen receptor from the system through degradation rather than just blocking its activity. The compounds promote ubiquitination and proteasomal degradation, physically removing the receptor from cells to eliminate the target for resistance development
Solution Approach 2:
Instead of blocking receptor activity (antagonism), the patent inverts the approach by promoting receptor degradation. This fundamental inversion of the mechanism of action transforms temporary blockade into permanent removal, overcoming resistance
3Reliability
If conventional estrogen receptor targeting agents are used, then some therapeutic effect is achieved, but tumor invasiveness is not sufficiently reduced
Solution Approach 1:
The patent changes the therapeutic parameter from receptor activity modulation to receptor quantity reduction. By inducing proteasomal degradation, the compounds achieve both therapeutic effect and reduced tumor invasiveness through sustained lower receptor levels
Data Source
AI summary
Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.



